86 results about "Low insulin" patented technology

The invention provides a new application of berberine in the treatment of metabolic syndrome. Large-sample polycentric and randomized double-blind prospective experiments reveal the effect of berberine on metabolism of glucose and lipid and clarify the interrelation and common changes of the metabolism of glucose and lipid before and after berberine treatment. The berberine is used as a broad spectrum antibiotic and clinical drug with high efficiency and low toxicity for a long time and can be taken chronically without obvious side effect. Results of researches indicate that the berberine can help sufferers of type II diabetes mellitus combined with blood lipid abnormality regulate disorder of saccharometabolism and lipid metabolism, lower insulin resistance, avoid central obesity and elevation of blood pressure, thereby showing the positive effect of the berberine on the treatment of metabolic syndrome. The invention provides the new clinical application of berberine in the treatment of metabolic syndrome for human for the first time, which establishes the importance of the new clinical application of traditional Chinese medicine in the treatment of metabolic syndrome and provides a new basis as well, thereby helping to promote the traditional medicine of China.

The invention discloses a method for providing a new intervention target for preparation of antihyperglycemic medicines and using the irisin into development of diabetes-related medicines to prepare relatively good medicines for treating diabetes. After STZ/HFD-induced mice with diabetes are subjected to subcutaneous injection with irisin, the fasting serum glucose level is significantly reduced; the insulin sensitivity is significantly improved; by irisin, gluconeogenesis is reduced and glycogen synthesis is increased; the application proves that irisin is capable of significantly improving glucose metabolic disorder and insulin resistance in diabetes, is an effective target for treating diabetes, and can be developed as a novel antihyperglycemic medicine or medicine target; and a new way and means are provided for detection and treatment of diabetes.

The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

The invention provides application of pinitol to pharmacy and health care product. Compared with the prior art, the invention has the beneficial effects that: novel medical application and health care application of a known compound is explored, and a new application field is developed; the product has rich source and simple preparation process, can be prepared into an oral preparation, an injection and tablet, and is convenient for use; the configured drug product or health care product has effects of increasing plasma levels of pinitol and D-chiro-inositol, and decreasing plasma insulin and glucose levels; and the configured drug product or health care product has effects of reducing the blood sugar value, insulin level, plasma lipid and plasma triglyceride.

The invention relates to application of total saponins in unripe siraitia grosvenorii fruit extract in preparation of an assistant hypoglycemic drug. Extract containing the total saponins with the content by weight of 60%-90% is extracted from unripe siraitia grosvenorii fruit with the growing period of 30 days-80 days, one of the effective ingredients mogroside II and mogroside III in the total saponins or a mixture of the effective ingredients mogroside II and mogroside III in the total saponins inhibits the activity of alpha-glucosidase in vitro and in vivo, the fasting blood-glucose level and the postprandial blood glucose level of a type-II diabetic mouse are lowered, and the activity of the insulin resistance index is reduced; in addition, new application of the total saponins in preparation of food or the drug for assisting in treating insulin resistance and type-II diabetes mellitus is achieved.

The invention provides a traditional Chinese medicine for curing type II diabete, which is Hubei dwarf lilyturf tuber hetetopolysaccharide extracted by taking Hubei dwarf lilyturf tuber as a raw material. The traditional Chinese medicine has obvious effects of reducing blood sugar of mice with the type II diabete, obvious effects of reducing insulin resistance and the effect strength of the traditional Chinese medicine has no statistical difference from that of rosiglitazone. Compared with the rosiglitazone, the hetetopolysaccharide can better reduce blood total cholesterol and triglycercide, improve ratio of high-density lipoprotein to low-density lipoprotein, and effectively prevent and curing arteriosclerosis and thrombosis.

The invention discloses detoxing and slimming biscuits and a making method thereof. The biscuits are made of the following raw materials: wheat flour, white kidney bean flour, wheat dietary fiber, soybean peptide powder, psyllium seed husk, konjac flour, semen pruni powder, vegetable oil, white granulated sugar, whole wheat flour, soybean protein isolate and skimmed milk powder. On the basis of reasonable use of the functional characteristic of resistance of resistant dextrin to digestive enzymes, the biscuits cannot be digested and absorbed in the digestive tract and can directly enter the large intestine. Therefore, the biscuits play various physiological roles of the dietary fiber and can have effects of lowering blood sugar, reducing blood fat, and maintaining the intestinal tract andthe like due to the characteristics of high digestion tolerance, low glycemic index, low insulin index, low calorie, high dissolubility and the like.

The invention relates to a compound recipe cyclocarya paliurus leaf preparation. The compound recipe cyclocarya paliurus leaf preparation consists of cyclocarya paliurus leaf and radix puerariae, preferably, 8 parts by weight of the compound recipe cyclocarya paliurus leaf preparation contains 4 parts by weight of the cyclocarya paliurus leaf and 4 parts by weight of the radix puerariae. The invention also provides an application of the compound recipe cyclocarya paliurus leaf preparation to preparation of medicines for clinical treatment of type 2 diabetes. Through contrast of medicine administration effects between different kinds of medicine groups, the effects of the compound recipe cyclocarya paliurus leaf preparation for reducing blood sugar level, improving impaired sugar tolerance,reducing insulin level and improving insulin resistance indexes are obviously better than effects of single use of the cyclocarya paliurus leaves and effects of single use of the radix puerariae, comprehensive effects are notable, synergistic reactions are achieved when the cyclocarya paliurus leaves and the radix puerariae are united, and a new selection and a new thinking are provided for controlling diabetes.

The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one of lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), at least one N-acetylated oligosaccharide different from LNnT and LNT, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in increasing insulin sensitivity and/or reducing insulin resistance. This composition optionally further comprises 2′-fucosyllactose (FL). This composition is particularly adapted for use in infants who were born preterm and/or who experienced IUGR, in pregnant women suffering from gestational diabetes and in children, adolescents, and adults suffering from insulin resistance and/or type II diabetes.

The present invention discloses a construction method for an IRTKS gene-knocked out mouse model. According to the method, homologous recombination is adopted, and a 2.0-kb PGK/Neo sequence is adopted to substitute for the exon1 sequence containing the ATG initiation codon in the mouse IRTKS gene so as to obtain the IRTKS gene-knocked out mouse model. The present invention further discloses the IRTKS gene-knocked out mouse model constructed by using the method, and the application of the model in diabetes research. According to the present invention, results of pathological analysis and detection of carbohydrate, insulin and the like confirmed that the IRTKS gene-knocked out mouse can produce hyperglycemia, hyperinsulinemia, impaired glucose tolerance, decreased insulin sensitivity and the like, and are consistent with the disease characteristics of human so as to provide the good animal model for study on the diabetes pathogenesis and evaluation and screening of the treatment drugs.

The invention discloses a glucose sensitive controlled release microballoon composition and a preparation method thereof. The medicine for treating the diabetes, the glucose oxidase (GOD) and the catalase (POD) are embedded in the microballoon. By taking the insulin as an example, when the in-vivo glucose concentration is raised, the glucose can be diffused to the surface of the microballoon and is oxidized by the GOD in the microballoon to form the gluconic acid, the pH value in the environment is reduced to about 3-5, the microballoon degradation and corrosion speed is rapidly increased and the insulin release speed is quickened; when the blood sugar concentration is controlled, the PH value is recovered to the physiological PH value of about 7.4, the microballoon degradation speed is reduced and the insulin release speed is slowed. When the blood sugar is raised again, the release behavior is repeated, the insulin presents a glucose-sensitive self-regulating release behavior, the POD can perform catalytic decomposition on the hydrogen peroxide to generate oxygen, the oxygen consumed in the microballoon GOD enzyme reaction is compensated and the enzyme active utilization rate is increased. The glucose sensitive controlled release microballoon composition can be used for solving the problem that the traditional medicine for treating the diabetes cannot perform self regulation to release the diabetes treating medicine according to the in-vivo blood sugar change.

The invention discloses a needle treatment device for insulin injection. The device comprises a box body, a needle head clamping button, a needle core and needle seat separation button and a needle core disinfection and melting button are fixedly mounted at the left end of the top of the box body in sequence from left to right; a guide rail is fixedly installed at the position, close to the top, in the box body, a driving motor is fixedly installed on one side of the guide rail, and the driving motor is fixedly connected with a lead screw through the output end of one side of the driving motor. The invention discloses the needle treatment device for insulin injection. The insulin syringe needle can be treated immediately after being used; a high-frequency electromagnetic coil heating method is adopted; the needle core and the needle base are separated and separately treated, the collected needle core is disinfected and melted through heating of the high-frequency electromagnetic coil,the risk that an insulin pen user is stabbed is effectively reduced, iatrogenic infection is reduced, the psychological pressure of injection personnel is reduced, and meanwhile the whole device is simple and easy to implement.

The invention discloses a traditional Chinese medicine composition for treating diabetes mellitus, which is prepared by the following components in parts by weight: 20 parts of radix puerariae, 10 parts of radix polygonati officinalis, 15 parts of snakegourd fruit roots, 10 parts of ophiopogon roots and 10 parts of schisandra chinensis. The traditional Chinese medicine composition is very remarkable in effect, can obviously reduce a fasting blood-glucose level of a T2DM (Type 2 Diabetes Mellitus) insulin resistance rat, can raise an insulin level, and can improve the sensibility of the model rat on insulin.

The invention relates to a preparation method of resistant starch. The preparation method comprises the following steps of: taking starch as a raw material, and adding an appropriate amount of quercetin in the gelatinization process of the starch to form a highly-dispersed quercetin-starch composite. As the quercetin has the function of restraining the activities of Alpha-glycuronide and Alpha-amylase, in the quercetin-starch composite, the quercetin has stronger interaction with starch molecules and influences the enzymolysis property of the starch. The composite is the novel resistant starch which can resist enzyme decomposition, slowly release glucose in body, has lower insulin reaction, can control blood sugar balance and reduce hunger sense and is especially suitable for diabetic patients; and the invention solves the problems of low product yield, complex production process, and the like in the production process of the resistant starch.

The invention relates to the technical field of probiotics, in particular to a composition of lactobacillus paracasei LC-37 and application of the composition in reducing blood sugar. According to the invention, the lactobacillus paracasei LC-37 has new functions of promoting the secretion of the glucagon-like peptide 1, reducing blood sugar and relieving the symptoms of diabetes mellitus; the lactobacillus paracasei LC-37 is further compounded with the dietary fibers, the GLP-1 secretion promoting effect of the lactobacillus paracasei LC-37 is remarkably improved, and the composition of the lactobacillus paracasei LC-37 and the dietary fibers can remarkably reduce the blood glucose of diabetic animals, relieve oral glucose tolerance damage, reduce the insulin resistance index and regulate blood fat. The traditional Chinese medicine composition can improve intestinal mucosal barrier and pancreatic tissue damage, has a certain relieving effect on type II diabetes, and is safe, reliable and free of side effects.

The invention provides a fructan consisting of 25 beta-D-fructoses and 1 alpha-D-glucose, and a method for preparing the fructan from Hubei dwarf lilyturf tuber serving as a raw material. The fructan has obvious effect of reducing blood sugar of mice with type 2 diabetes, simultaneously improves the sugar tolerance of the mice with the type 2 diabetes, and obviously enhances the expression of insulin receptor (InsR), insulin receptor substrate (IRS-1), protein kinase and phosphatidylinositol3-kinase (PI3-K) to further accelerate the glucose to be converted into glycogen and improve the activities of glucose-6-phosphate and glucose-6-phophatase so as to obvious reduce the insulin resistance.

The present invention provides a preoperative enteral nutritional composition for reducing the stress response of surgical treatment to a patient. The composition comprises human milk oligosaccharide(HMO), maltodextrin and fructose. The composition can accelerate tissue repair and wound healing, reduce insulin resistance, reduce postoperative complication occurrence rate and mortality, acceleratepatient rehabilitation, shorten hospitalization days and improve patient prognosis.

The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum HOM3201 strain, a viable bacterium preparation containing the lactobacillus plantarum HOM3201 strain as well as a preparation method and application of the lactobacillus plantarum HOM3201 strain. The preservation number of the lactobacillus plantarum HOM3201 strain is CGMCC (China General Microbiological Culture Collection Center) No. 22700. The lactobacillus plantarum HOM3201 strain can significantly reduce the fasting blood glucose level of insulin-resistant glucose/lipid metabolism disorder model rats, increase the tolerance of the body to glucose, and reduce the insulin resistance index.

Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R¹-R¹⁴, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders.